Literature DB >> 22448187

Outcome in a patient with systemic lupus erythematosus and concurrent chronic hepatitis B infection.

Lyubomir Marinchev1, Krasimir Antonov, Veneta Peytcheva, Zlatimir Kolarov.   

Abstract

A 35-year-old Caucasian woman with proven systemic lupus erythematosus (SLE) had been effectively managed with hydroxychloroquine and methylprednisolone for many years. In 2005 she was admitted to the rheumatology clinic with a flare up of the disease and with proteinuria of 3.2 g/24 h. Renal biopsy was performed and revealed diffuse proliferative nephritis. Before the renal biopsy a positive HB(s)Ag was found with high virus replication (hepatitis B virus (HBV)-DNA-4 170 000 copies/ml). Liver biopsy revealed chronic hepatitis with minimal activity (TAIS=1). Lamivudine was administered with concomitant maintenance corticosteroid treatment, but without antimalarials. Pulsed methylprednisolone treatment for diffuse lupus nephritis was begun on the background of lamivudine therapy. The liver enzymes returned to normal values, HBV replication was suppressed, and the proteinuria disappeared. At present the patient is not being treated with lamivudine and there are no objective signs of nephritis and hepatitis, or HBV activation.

Entities:  

Year:  2010        PMID: 22448187      PMCID: PMC3028114          DOI: 10.1136/bcr.09.2009.2273

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  8 in total

Review 1.  Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.

Authors:  Winnie Yeo; Philip J Johnson
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

2.  A case-control study of serious autoimmune adverse events following hepatitis B immunization.

Authors:  David A Geier; Mark R Geier
Journal:  Autoimmunity       Date:  2005-06       Impact factor: 2.815

3.  Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient.

Authors:  S Ito; K Nakazono; A Murasawa; Y Mita; K Hata; N Saito; M Kikuchi; K Yoshida; M Nakano; F Gejyo
Journal:  Arthritis Rheum       Date:  2001-02

4.  Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis.

Authors:  M Y Mok; W L Ng; M F Yuen; R W Wong; C S Lau
Journal:  Clin Exp Rheumatol       Date:  2000 May-Jun       Impact factor: 4.473

Review 5.  Rheumatologic manifestations of hepatic diseases.

Authors:  Zhao-Chun Chi; Su-Zhen Ma
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2003-02

6.  [Reactivation of hepatitis B following withdrawal of chloroquine].

Authors:  B Helbling; J Reichen
Journal:  Schweiz Med Wochenschr       Date:  1994-05-07

7.  Outcomes of chronic hepatitis B infection in Oriental patients with rheumatic diseases.

Authors:  Bernard Y H Thong; Ee Tzun Koh; Hiok Hee Chng; Wan Cheng Chow
Journal:  Ann Acad Med Singapore       Date:  2007-02       Impact factor: 2.473

8.  Reactivation of hepatitis B virus in rheumatologic patients receiving immunosuppressive agents.

Authors:  Feng-Chiao Tsai; Song-Chou Hsieh; Ding-Shinn Chen; Jin-Chuan Sheu; Chien-Hung Chen; Ding-Shinn Chen
Journal:  Dig Dis Sci       Date:  2006-08-22       Impact factor: 3.487

  8 in total
  1 in total

1.  Hepatitis B carrier state among SLE patients: case-control study.

Authors:  Omer Gendelman; Naim Mahroum; Doron Comaneshter; Pnina Rotman-Pikielny; Arnon D Cohen; Howard Amital; Michael Sherf
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.